Table 1.

Patient characteristics and pharmacological treatment.

Pt	Gender/age (yr)	Body distribution	Isolated or combined	Etiology	Pre-operative medical treatment	Post-operative medical treatment
1	M/8	Generalized	Combined (spasticity)	Mitochondrial disorder	Gabapentin 100 mg; intrathecal baclofen 3 ug/hr	Unchanged
2	M/8	Generalized	Isolated	Idiopathic	THP 20 mg	No
3	M/18	Segmental	Isolated	Idiopathic	THP 24 mg; BTX	THP 24 mg
4	F/22	Generalized	Isolated	ACTB mutation	THP 16 mg; tramadol 50 mg	THP 12 mg; clonazepam 1.5 mg; clozapine 18.75; BTX
5	F/32	Segmental	Isolated	Idiopathic	Ibuprofen; BTX	No
6	M/9	Generalized	Isolated	DYT-THAP1	THP 21 mg; baclofen 12.5 mg	THP 11 mg
7	M/22	Segmental	Isolated	TTPA	Vitamin E	Unchanged
8	M/47	Generalized	Combined (spasticity)	Cerebral palsy	Antidepressants	Unchanged
9	M/53	Segmental	Isolated	Idiopathic	Clonazepam 0.5 mg; BTX	BTX
10	F/65	Segmental	Combined (parkinsonism)	Idiopathic	Pramipexole; L-dopa; Diazepam 5 mg; BTX	Pramipexole; L-Dopa
11	F/48	Generalized	Isolated	ACTB mutation	THP 12 mg; clozapine 12.5 mg; oxazepam 10 mg; diclofenac; BTX antidepressant	THP 12 mg; clozapine 12.5 mg; antidepressant
12	F/63	Segmental	Isolated	Idiopathic	Clonazepam 2.5 mg	Clonazepam 0.5 mg
13	M/62	Segmental	Isolated	Idiopathic	BTX	Clonazepam 1.0 mg; BTX
14	F/8	Generalized	Combined (spasticity)	Cerebral palsy	THP 1.5 mg; baclofen 12 mg; gabapentin 600 mg; clonazepam 0.5 mg	Unchanged
15	F/63	Segmental	Isolated	Idiopathic	No	No

ACTB: beta-actin gene; BTX: botulinum toxin injections; THP: trihexiphenidyl; TTPA α-tocopherol transfer protein – vitamin E.